The 20 references in paper E. Novikova S., A. Komarov L., E. Gus’kova V., O. Shakhmatova O., A. Deyev D., A. Dobrovolsky B., A. Samko N., E. Panchenko P., Е. Новикова С., А. Комаров Л., Е. Гуськова В., О. Шахматова О., А. Деев Д., А. Добровольский Б., А. Самко Н., Е. Панченко П. (2017) “ДОСТАТОЧНО ЛИ ШКАЛЫ SYNTAX ДЛЯ ОЦЕНКИ РИСКА БОЛЬНЫХ, ПОДВЕРГАЕМЫХ ПЛАНОВЫМ ЧРЕСКОЖНЫМ КОРОНАРНЫМ ВМЕШАТЕЛЬСТВАМ? // IS THE SYNTAX SCORE SUFFICIENT TO ASSESS THE RISK FOR PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTIONS?” / spz:neicon:aterotromboz:y:2017:i:1:p:80-93

1
Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet,2013, 381(9867): 629-638.
(check this in PDF content)
2
http: //www.syntaxscore.com/.
(check this in PDF content)
3
Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg,1999, 16(1): 9-13.
(check this in PDF content)
4
Peterson ED, Dai D, DeLong ER, et al. Contemporary mortality risk prediction for percutaneous coronary intervention: results from
(check this in PDF content)
5
8,398 procedures in the National Cardiovascular Data Registry. J Am Coll Cardiol, 2010, 55(18): 1923-1932. 5. Byrne A, Serruys PW, Baumbach A et al. Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. Eur Heart J, 2015 Oct 7, 36(38): 2608-20.
(check this in PDF content)
6
2014 ESC/EACTS Guidelines on myocardial revascularization The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2014 Oct 1, 35(37): 2541-619.
(check this in PDF content)
7
Гуськова Е.В., Панченко Е.П., Комаров А.Л., Добровольский А.Б., Самко А.Н. Остаточная реактивность тромбоцитов к АДФ и риск кровотечений у больных стабильной ИБС, получающих двойную антитромбоцитарную терапию в связи с плановым чрескожным коронарным вмешательством. Российский кардиологический журнал, 2015, 3(119): 35-42.
(check this in PDF content)
8
Комаров А.Л., Илющенко Т.А., Шахматова О.О., Деев А.Д., Самко А.Н., Панченко Е.П. Сравнительная эффективность консервативного и инвазивного лечения больных со стабильной формой ишемической болезни сердца (по результатам пятилетнего проспективного наблюдения). Кардиология, 2012, 52(8): 4-14.
(check this in PDF content)
9
Serruys PW, Morice MC, Kappetein AP, et al., for the SYNTAX Investigators. Percutaneous coronary intervention versus coronary artery bypass grafting for severe coronary artery disease. N Engl J Med,2009, 360: 961-72.
(check this in PDF content)
10
Garg S, Sarno G, Girasis C, et al. A patient-level pooled analysis assessing the impact of the SYNTAX (Synergy Between Percutaneous Coronary Intervention WithTaxus and Cardiac Surgery) score on 1-year clinical outcomes in 6,508 patients enrolled in contemporary coronary stent trials. J Am Coll Cardiol Interv, 2011, 4: 645-53.
(check this in PDF content)
11
Gijsberts CM, Seneviratna A, Hoefer IE, et al. InterEthnic Differences in Quantified Coronary Artery Disease Severity and All-Cause Mortality among Dutch and Singaporean Percutaneous Coronary Intervention Patients. PLoS One, 2015, 10(7): e0131977. Publishedonline 2015 Jul 6. doi: 10.1371/journal.pone.0131977.
(check this in PDF content)
12
Xu B, GОnОreux Ph, Yang Y, et al. Validation and Comparison of the Long-Term Prognostic Capability of the SYNTAX Score-II Among 1,528 Consecutive patients Who Underwent Left Main Percutaneous Coronary Intervention. J Am Coll Сardiol Intv,2014, 7: 1128-37.
(check this in PDF content)
13
Palmerini T, CalabrШ P, Piscione F, et al. Impact of Gene Polymorphisms, Platelet Reactivity, and the SYNTAX Score on 1-Year Clinical Outcomes in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention The GEPRESS Study. J Am Coll Cardiol Intv, 2014, 7: 1117-27.
(check this in PDF content)
14
Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet, 2013, 382: 614–23.
(check this in PDF content)
15
Komarov A, Ilyushchenko T, Dobrovolsky A et al. D-dimer, plasmin-antiplasmin complex and matrix metalloproteinase 2 as markers of cardiovascular events in patients with stable coronary disease. Abstract of the ESC Congress 2012. European Heart Journal, 2012, 33(Abstract Supplement): 305.
(check this in PDF content)
16
Folsom AR, Aleksic N, Park E, et al. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol, 2001, 21(4): 611-617.
(check this in PDF content)
17
Smith A, Patterson C, Yarnell J, et al. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation, 2005, 112(20): 3080-3087.
(check this in PDF content)
18
Morange PE, Bickel C, Nicaud V, et al. Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. Arterioscler Thromb Vasc Biol, 2006, 26(12): 2793-2799.
(check this in PDF content)
19
Гуськова Е.В. Факторы, определяющие безопасность двойной антитромбоцитарной терапии после плановых чрескожных коронарных вмешательств: Автореф. дис. ... канд. мед. наук. М.: 11-й ФОРМАТ,
(check this in PDF content)
20
6. 24 с.
(check this in PDF content)